Beverly Tang
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$11.5MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $11.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 3, 2026 | NIH | SBIR Phase II DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME | $1.2M | STARLIGHT CARDIOVASCULAR INC |
| May 13, 2026 | NIH | SBIR Phase II DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY | $1000K | STARLIGHT CARDIOVASCULAR INC |
| Feb 20, 2025 | NIH | SBIR Phase II DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME | $1000K | STARLIGHT CARDIOVASCULAR INC |
| Dec 9, 2024 | NIH | SBIR Phase II DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY | $1000K | STARLIGHT CARDIOVASCULAR INC |
| Jun 11, 2024 | NIH | SBIR Phase II Administrative Supplement to Promote Diversity in MedTech Through Development of Pulmonary Flow Restrictors | $88K | STARLIGHT CARDIOVASCULAR INC |
| Mar 20, 2024 | NIH | SBIR Phase II DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME | $1000K | STARLIGHT CARDIOVASCULAR INC |
| Jul 14, 2023 | NIH | SBIR Phase II DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY | $902K | STARLIGHT CARDIOVASCULAR INC |
| Sep 19, 2022 | NIH | SBIR Phase II DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY | $1.3M | STARLIGHT CARDIOVASCULAR INC |
| Sep 19, 2022 | NIH | SBIR Phase II DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY | $2.2M | STARLIGHT CARDIOVASCULAR INC |
| Feb 15, 2022 | NIH | SBIR Phase I DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME | $448K | STARLIGHT CARDIOVASCULAR INC |
| Feb 15, 2022 | NIH | SBIR Phase I DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME | $448K | STARLIGHT CARDIOVASCULAR INC |
| Aug 6, 2021 | NIH | SBIR Phase I DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY | $493K | STARLIGHT CARDIOVASCULAR INC |
| Aug 6, 2021 | NIH | SBIR Phase I DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY | $493K | STARLIGHT CARDIOVASCULAR INC |
Peer ranks
Federal funding#58
Awards as PI#77
Patents#505
Companies
- STARLIGHT CARDIOVASCULAR INCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.